NCT05361655

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

Real-World Treatment Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor as 1st Line Therapy in Metastatic Breast Cancer

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 2,888 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A retrospective study of de-identified (to preserve patient privacy) patient information from the Flatiron Health Analytic Database to compare effectiveness (i.e., overall survival) of first line palbociclib + aromatase inhibitor (AI) versus AI alone treatment in postmenopausal women or men with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (MBC) in the United States clinical practices.

Conditions

• Metastatic Breast Cancer

Interventions

Type	Name	Description
DRUG	Palbociclib + an aromatase inhibitor	Palbociclib + an aromatase inhibitor therapy
DRUG	Aromatase inhibitor	Aromatase inhibitor therapy

Timeline

• Start date: 2021-09-01
• Primary completion: 2021-09-01
• Completion: 2021-09-01
• First posted: 2022-05-05
• Last updated: 2024-06-07
• Results posted: 2024-06-07

Locations

1 site across 1 country: United States